Introduction
With the development of interventional technology and medication strategies, the number of cardiac catheterization procedures being performed continues to grow rapidly. 1 Simultaneously, the incidence of contrast-induced nephropathy (CIN), a common and well-known complication which occurs following coronary angiography (CAG) or percutaneous coronary intervention (PCI) and is significantly associated with renal and cardiovascular adverse events and long-term mortality, has also increased submit your manuscript | www.dovepress.com
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Wang et al gradually. 2, 3 Since the effective treatment measures for CIN are unknown, risk identification is important for ensuring that high-risk patients receive appropriate prophylactic measures and postoperative monitoring. 4 Heart failure (HF) is a common and deteriorating condition, which has a high prevalence of ischemic origin. 5 With the advancement of HF or cardiac impairment, adverse hemodynamic state results in inadequate renal perfusion and accelerates the renal impairment after contrast medium (CM) administration. 6, 7 Previous studies indicated that HF is one of the critical factors influencing the development of CIN. 8, 9 Left ventricular ejection fraction (LVEF) is another parameter that reflects the cardiac function and a useful term to categorize the type of HF, such as HF with reduced ejection fraction (HFrEF; EF ,40%), HF with mid-range ejection fraction (HFmrEF; EF 40%-49%) and HF with preserved ejection fraction (HFpEF; EF $50%). 10 However, the association between LVEF and the risk of CIN is still controversial. [11] [12] [13] [14] Therefore, the purpose of our study was to analyze the association of LVEF with CIN and long-term mortality following CAG/PCI in patients with HF.
Methods study population
This prospective observational study was conducted at the Guangdong General Hospital from April 2009 to December 2013. We included patients aged .18 years who had HF, defined as New York Heart Association (NYHA) or Killip class .1, and were undergoing PCI/CAG. Based on the protocol, exclusion criteria included pregnancy, malignancy, cardiovascular surgery or endovascular repair, end-stage renal disease or renal replacement, treatment with nephroprotective (eg, N-acetylcysteine) or nephrotoxic (eg, glucocorticoids, aminoglycosides) drugs and exposure to CM within the previous 7 days. In addition, patients who had missing preoperative or postoperative creatinine values (n=87) and LVEF (n=448) were excluded.
Biochemical investigations
Serum creatinine (SCr) concentrations were measured at admission and within 24, 48 and 72 h after CM administration. Other biochemical indicators were measured in the morning prior to the procedure. The Modification of Diet in Renal Disease equation was used to calculate the estimated glomerular filtration rate (eGFR), 15 and the echocardiography examination was used to evaluate the LVEF. A baseline eGFR ,60 mL/min/1.73 m 2 was defined as renal insufficiency. 16 Furthermore, NYHA class .2 or Killip class .1 was defined as advanced HF.
17,18
Cardiac catheterization
Cardiac catheterization was performed according to the standard clinical practice, by experienced interventional cardiologists. Non-ionic, low-osmolality CM was used for all patients. The type of stents was selected by the interventional cardiologists according to operative requirements. All patients received intravenous infusion of normal saline 2-12 h before and 6-24 h after the procedure at a speed of 0.5-1.0 mL/kg/h. The hydration time and speed and the clinical medication were chosen based on the patient condition.
Clinical end points and follow-up
The primary end point of this study was the development of CIN, defined as an absolute increase of $0.5 mg/dL or a relative increase of $25% from baseline SCr level within 48-72 h after CM exposure (CIN 0.5 or 25% ). 19 Additional end point included another criteria of CIN, defined as an absolute increase of $0.3 mg/dL or a relative increase of $50% (CIN 0.3 or 50% ) and an absolute increase of $0.5 mg/dL (CIN 0.5 ), 20 and all-cause mortality. All patients included in this study were followed up by telephone or office visits at 1, 6, 12, 24 and 36 months after discharge. Adverse events were recorded on the case report form.
This study was performed according to the Declaration of Helsinki, and the ethics committee of the Guangdong General Hospital approved the study protocol. Written informed consent was obtained from the patients involved in the study.
statistical analysis
Patients were divided into three groups based on the level of LVEF according to the 2016 European Society of Cardiology guideline for HF. 10 For continuous variables, ANOVA was used for normally distributed data (described as mean ± standard deviation), and Wilcoxon rank-sum test was conducted for non-normal distributions (described as interquartile range). For categorical variables, χ 2 test or Fisher's exact test was used (described as absolute values and percentages). Multivariable logistic regression and Cox proportional hazards regression analyses were performed to identify the association of LVEF with CIN and long-term mortality, respectively. HFpEF was considered as the reference group. The effect of HFmrEF and HFrEF on outcomes was estimated and was compared with the reference group. Kaplan-Meier method was used to describe the all-cause mortality by log-rank tests. All statistical analyses were performed with SPSS software version 22.0 (IBM Corporation, Armonk, NY, USA) and R software (version 3. Team, Vienna, Austria). A two-tailed P,0.05 was considered statistically significant. Compared to the patients with HFpEF, patients with HFrEF were more likely to have advanced HF, renal insufficiency and prior myocardial fraction. Furthermore, those in the HFrEF group had lower systolic blood pressure on admission and were less likely to have a history of hypertension. However, age, gender, smoking, hyperlipidemia and history of coronary artery bypass grafting were similar among the three groups.
Results
Baseline demographics and characteristics
On admission, patients with HFrEF had higher SCr and N-terminal pro-brain natriuretic peptide concentrations, but Abbreviations: hFreF, heart failure with reduced ejection fraction; hFmreF, heart failure with mid-range ejection fraction; hFpeF, heart failure with preserved ejection fraction; sBP, systolic blood pressure; DBP, diastolic blood pressure; hF, heart failure; Mi, myocardial infarction; CaBg, coronary artery bypass grafting; sCr, serum creatinine; eGFR, estimated glomerular filtration rate; NT-proBNP, N-terminal pro-brain natriuretic peptide; LVEF, left ventricular ejection fraction; TG, triglyceride; CHO, cholesterol; lDl, low-density lipoprotein; hDl, high-density lipoprotein; hba1c, hemoglobin a1c; hgB, hemoglobin; aCei, angiotensin-converting enzyme inhibitor; aRB, angiotensin receptor blocker; PCi, percutaneous coronary intervention; CM, contrast medium. (Table 3) . association between lVeF, Cin and longterm mortality
The mean follow-up period was 2.30±0.93 years. Log-rank analyses indicated that patients with lower LVEF were associated with higher mortality rate (log-rank, P,0.001). The Kaplan-Meier curve is shown in Figure 2 . After adjusting for the confounders which were associated with longterm mortality, multivariate Cox regression showed that HFrEF was an independent predictor of mortality (HFrEF vs HFpEF: adjusted hazard ratio [HR] =2.88, 95% CI, 1.77-4.69; P,0.001; HFmrEF vs HFpEF: HR =1.55, 95% CI, 0.95-2.53; P=0.079) ( Table 4) .
Moreover, patients who developed CIN 0.5 or 25% had higher rate of all-cause mortality than those without during the follow-up. Similar results were found in those who developed CIN 0.3 or 50% or CIN 0.5 ( Figure 3 ).
Discussion
To our knowledge, this is the first study to describe the clinical characteristics and investigate the association of LVEF with CIN and long-term mortality following CAG/PCI in patients with HF. Our data showed that patients with lower LVEF were more likely to have comorbidities and develop CIN. However, advanced HF was significantly associated with an increased risk of CIN. In addition, age .75 years, Abbreviations: Cin, contrast-induced nephropathy; hFreF, heart failure with reduced ejection fraction; hFmreF, heart failure with mid-range ejection fraction; hFpeF, heart failure with preserved ejection fraction. Abbreviations: Cin, contrast-induced nephropathy; hFreF, heart failure with reduced ejection fraction; hFmreF, heart failure with mid-range ejection fraction; hFpeF, heart failure with preserved ejection fraction; Ci-aKi, contrast-induced acute kidney injury. emergency PCI and use of IABP were the independent risk factors for CIN. It is noteworthy that reduced LVEF was an independent predictor of long-term mortality following CAG/PCI. In recent years, the proportion of patients with HFpEF has increased significantly, 21 with a prevalence of 71%-74% being reported in large-cohort studies from Western and Asians countries. [22] [23] [24] Additionally, myocardial ischemia has been demonstrated as the major etiology of HF. 25, 26 However, the incidence of HFpEF among these patients following CAG/PCI has not been analyzed. As observed in our analysis, the incidence of HFpEF was highest in the study population (72.98%), which was similar to the prior analyses. The high prevalence of HFpEF suggests that it should be given high priority in risk assessment.
Characteristics of HFmrEF were demonstrated to be intermediate between those of HFrEF and HFpEF. 27 Similar results were found in the patients with HF following CAG/ Abbreviations: CIN, contrast-induced nephropathy; OR, odds ratio; CI, confidence interval; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; hFmreF, heart failure with mid-range ejection fraction; DM, diabetes mellitus; hF, heart failure; Mi, myocardial infarction; PCi, percutaneous coronary intervention; CM, contrast medium; iaBP, intra-aortic balloon pump.
Figure 2
Cumulative rate of all-cause mortality during the follow-up in patients with hFreF, hFmreF and hFpeF. Abbreviations: hFreF, heart failure with reduced ejection fraction; hFmreF, heart failure with mid-range ejection fraction; hFpeF, heart failure with preserved ejection fraction. Abbreviations: HR, hazard ratio; CI, confidence interval; HFpEF, heart failure with preserved ejection fraction; hFreF, heart failure with reduced ejection fraction; hFmreF, heart failure with mid-range ejection fraction; DM, diabetes mellitus; iaBP, intra-aortic balloon pump; hF, heart failure; PCi, percutaneous coronary intervention.
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Wang et al PCI. Our present study indicated that HFmrEF patients were closer to the HFrEF patients in terms of use of diuretics and IABP and presence of comorbidities, such as advanced HF, renal insufficiency and hypotension, but closer to the HFpEF in terms of use of statins, all of which have been demonstrated as contributing factors for CIN. 19, 28 Moreover, patients with HFmrEF were more likely to undergo emergency PCI than other groups. Based on those characteristics, the incidence of CIN was highest in this particular population. In recent years, CIN has been reported as the third most common cause of hospital-acquired renal failure. 3 Therefore, effective pre-procedural identification of patients at high risk of CIN is vital.
LVEF is the most widely used parameter to evaluate cardiac functions associated with hemodynamic instability, and consequently causes inadequate renal perfusion. However, the association between LVEF and CIN still remains controversial. An observational study by Shacham et al 11 included 386 patients undergoing PCI and found that patients with worsened LVEF had significantly higher rate of CIN compared with those with LVEF $45% (14.4% vs 5.7%; P=0.02). Moreover, worsened LVEF was an independent predictor of CIN. Similar results were found in another extensive cohort study, and a risk score of CIN was named AGEF, including advanced age, depressed LVEF and reduced eGFR. 12, 29 However, studies conducted by Kurtul 
893
association of lVeF with Cin and mortality et al 13 and Barbieri et al 14 showed an opposite effect after adjusting for several confounders. As observed in all the above-mentioned studies, only a small number of patients with HF were included, and consequently, those studies were unable to analyze the association between LVEF and CIN. Furthermore, HF, as an important risk factor of CIN, 8, 19 was not included in the multivariate analysis. In contrast, our study included sufficient patients with HF and adjusted for the potential confounders to investigate the association of LVEF with CIN following CAG/PCI. Previous studies indicated that the incidence of CIN in those with segment elevation myocardial infarction after PCI to be ranged from 10% to 20%. The potential factors such as impaired hemodynamic stability, large CM dose and insufficient prophylactic hydration led to higher risk of CIN in this particular group. In addition, inflammatory response and neurohumoral factors were also involved in this progress. 30 Therefore, emergency PCI was significantly and independently related to the risk of CIN. 31, 32 Recently, Duan et al 33 developed a simple model for early prediction of CIN, which indicated that emergency PCI was a significant influencing factor in this model. Similarly, emergency PCI increased the risk of CIN in our analysis. Therefore, more prophylactic measures and attention should be paid in this particular population.
The physiopathology of CIN remains poorly understood. Nevertheless, hemodynamic deterioration plays a significant role in the process. Worsened cardiac function contributes to the hemodynamic instability, which reduces effective renal blood flow, consequently trigging renin-angiotensin, activating sympathetic nervous system and increasing inflammatory factors and oxygen radical levels, all of which contribute to the development of CIN. 34 Therefore, among the eight variables from a classical risk assessment model for CIN, three (hypotension, advanced HF and use of IABP) are directly reflecting worsened cardiac function. 8 In addition, a high NYHA class reflects not only advanced HF but also adverse hemodynamic parameters 35 which accelerate the renal hypoperfusion and potentiate CIN. Therefore, it is likely that advanced HF plays an important role in the development of CIN in patients with HF.
Furthermore, previous studies suggested that patients with HFrEF experienced higher mortality compared to those with HFpEF, whereas others have indicated similar outcomes among the groups. [36] [37] [38] The marked disparity in long-term prognosis may contribute to the different inclusion criteria and various cut-offs of LVEF to define the type of HF. According to the classification of HF from guideline, 10 our data demonstrated that HFrEF in patients increased the risk of all-cause mortality. Therefore, early identification of patients at high risk of mortality may assist in directing treatment.
limitations
There are several limitations in this study. First, this was a prospective, observational and a single-center study. Therefore, the risk of bias cannot be ruled out, although we attempted to adjust for the confounding factors. Therefore, large-scale multicenter clinical trials are needed before these conclusions can be applied elsewhere. Second, variation in measurement times may lead to missed post-procedure peak levels of creatinine and may underestimate the true incidence of contrastinduced acute kidney injury. Third, as the study was limited to patients with HF, we were unable to extend the results to patients without HF. Fourth, the diagnosis of HF was based on the clinical evaluation, which has limited reliability.
Conclusion
Our data indicated that in patients with HF, not worsened LVEF but advanced HF was significantly associated with an increased risk of CIN following CAG/PCI. In addition, the reduced LVEF (HFrEF group) was an independent predictor of long-term mortality. The predictive value of worsened LVEF and advanced HF for CIN and mortality following cardiac catheterization needs to be investigated in patients with HF in large multicenter clinical trials.
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